1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Opioid-Induced Constipation (OIC) Global Clinical Trials Review, H1, 2014

Opioid-Induced Constipation (OIC) Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Opioid-Induced Constipation (OIC) Global Clinical Trials Review, H1, 2014" provides data on the Opioid-Induced Constipation (OIC) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Opioid-Induced Constipation (OIC). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Opioid-Induced Constipation (OIC). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Opioid-Induced Constipation (OIC) Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Opioid-Induced Constipation (OIC) 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Opioid-Induced Constipation (OIC) to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Opioid-Induced Constipation (OIC) to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Opioid-Induced Constipation (OIC) 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Opioid-Induced Constipation (OIC) 33
Oct 31, 2013: Synergy Pharmaceuticals Initiates Phase 2 Study of SP-333 in Patients with Opioid-Induced Constipation 33
Oct 14, 2013: AstraZeneca Announces New Safety Data For Naloxegol In Patients with Opioid-Induced Constipation 33
Oct 02, 2013: Synergy Pharmaceuticals Announces Plans to Initiate a Phase 2 Study of SP-333 for Opioid-Induced Constipation 34
Jul 18, 2013: Cubist Enrolls First Patient in Phase 3 Efficacy Studies Evaluating Bevenopran for the Treatment of Opioid-Induced Constipation 34
Feb 26, 2013: AstraZeneca Announces Results From Long-term Safety Trial Of Naloxegol In Patients With Opioid-induced Constipation 35
Clinical Trial Profiles 36
Clinical Trial Overview of Top Companies 36
Salix Pharmaceuticals Ltd. 36
Clinical Trial Overview of Salix Pharmaceuticals Ltd. 36
AstraZeneca PLC 38
Clinical Trial Overview of AstraZeneca PLC 38
Mundipharma International Limited 40
Clinical Trial Overview of Mundipharma International Limited 40
Shionogi and Co., Ltd. 41
Clinical Trial Overview of Shionogi and Co., Ltd. 41
Cubist Pharmaceuticals, Inc. 42
Clinical Trial Overview of Cubist Pharmaceuticals, Inc. 42
Theravance, Inc. 43
Clinical Trial Overview of Theravance, Inc. 43
Pfizer Inc. 44
Clinical Trial Overview of Pfizer Inc. 44
Novartis AG 45
Clinical Trial Overview of Novartis AG 45
Alkermes Plc 46
Clinical Trial Overview of Alkermes Plc 46
Alkermes Inc. (Inactive) 47
Clinical Trial Overview of Alkermes Inc. (Inactive) 47
Clinical Trial Overview of Top Institutes / Government 48
Friedrich-Schiller-Universitat Jena 48
Clinical Trial Overview of Friedrich-Schiller-Universitat Jena 48
The University of Vermont 49
Clinical Trial Overview of The University of Vermont 49
St. John's Health System 50
Clinical Trial Overview of St. John's Health System 50
VU University Medical Center 51
Clinical Trial Overview of VU University Medical Center 51
Shriners Hospitals for Children 52
Clinical Trial Overview of Shriners Hospitals for Children 52
Kuopio University Hospital 53
Clinical Trial Overview of Kuopio University Hospital 53
British Columbia Cancer Agency 54
Clinical Trial Overview of British Columbia Cancer Agency 54
UMC Utrecht Holding BV 55
Clinical Trial Overview of UMC Utrecht Holding BV 55
Ullevaal University Hospital 56
Clinical Trial Overview of Ullevaal University Hospital 56
Five Key Clinical Profiles 57
Appendix 138
Abbreviations 138
Definitions 138
Research Methodology 139
Secondary Research 139
About GlobalData 140
Contact Us 140
Disclaimer 140
Source 141

List of Tables
Opioid-Induced Constipation (OIC) Therapeutics, Global, Clinical Trials by Region, 2014* 7
Opioid-Induced Constipation (OIC) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Opioid-Induced Constipation (OIC) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Opioid-Induced Constipation (OIC) to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Opioid-Induced Constipation (OIC) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Opioid-Induced Constipation (OIC) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Opioid-Induced Constipation (OIC) to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Opioid-Induced Constipation (OIC) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Opioid-Induced Constipation (OIC) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Opioid-Induced Constipation (OIC) Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Opioid-Induced Constipation (OIC) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Opioid-Induced Constipation (OIC) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Opioid-Induced Constipation (OIC) Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Opioid-Induced Constipation (OIC) Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Opioid-Induced Constipation (OIC) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Salix Pharmaceuticals Ltd., 2014* 36
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 38
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Mundipharma International Limited, 2014* 40
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Shionogi and Co., Ltd., 2014* 41
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cubist Pharmaceuticals, Inc., 2014* 42
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Theravance, Inc., 2014* 43
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 44
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 45
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Alkermes Plc, 2014* 46
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Alkermes Inc. (Inactive), 2014* 47
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Friedrich-Schiller-Universitat Jena, 2014* 48
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Vermont, 2014* 49
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials Market, Global, Clinical Trials by St. John's Health System, 2014* 50
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials Market, Global, Clinical Trials by VU University Medical Center, 2014* 51
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Shriners Hospitals for Children, 2014* 52
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Kuopio University Hospital, 2014* 53
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials Market, Global, Clinical Trials by British Columbia Cancer Agency, 2014* 54
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials Market, Global, Clinical Trials by UMC Utrecht Holding BV, 2014* 55
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Ullevaal University Hospital, 2014* 56

List of Figures
Opioid-Induced Constipation (OIC) Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Opioid-Induced Constipation (OIC) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Opioid-Induced Constipation (OIC) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Opioid-Induced Constipation (OIC) to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Opioid-Induced Constipation (OIC) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Opioid-Induced Constipation (OIC) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Opioid-Induced Constipation (OIC) to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Opioid-Induced Constipation (OIC) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Opioid-Induced Constipation (OIC) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Opioid-Induced Constipation (OIC) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Opioid-Induced Constipation (OIC) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Opioid-Induced Constipation (OIC) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Opioid-Induced Constipation (OIC) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Opioid-Induced Constipation (OIC) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
GlobalData Methodology 139

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
North America Opioid Market Analysis By Product, By Application And Segment Forecasts To 2024

North America Opioid Market Analysis By Product, By Application And Segment Forecasts To 2024

  • $ 4950
  • Industry report
  • August 2016
  • by Grand View Research

The North America opioid market is expected to reach USD 18.5 billion by 2024, according to a new report by Grand View Research, Inc. Favorable regulations and healthcare reforms are providing an environment, ...

PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ERA

PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ERA

  • $ 3080
  • Industry report
  • September 2016
  • by MP Advisors

Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline for Abuse Deterrent drug formulation NDA & ANDA (solid oral) filing and CDC guideline for Prescribing ...

Global and Chinese N, N-diethyl-p-phenylenediamine hydrochloride Industry, 2016 Market Research Report

Global and Chinese N, N-diethyl-p-phenylenediamine hydrochloride Industry, 2016 Market Research Report

  • $ 3000
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese N, N-diethyl-p-phenylenediamine hydrochloride Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global N, N-dieth ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.